Phosplatin Therapeutics Inc.

[On Demand]
A privately held, clinical-stage pharmaceutical company in Phase 2 development with lead immunotherapeutic candidate PT-112, a novel, small molecule immunogenic cell death (ICD) inducer with proven activity in disease settings with limited treatment options.

PT-112 offers a unique combination of advantages. As the best-in-class ICD inducer, PT-112 has demonstrated durable single-agent activity in multiple solid tumors and in multiple myeloma, as well as synergy in combination with PD-L1 immune checkpoint inhibition. Its pleiotropic MoA is not subject to common drug-resistance pathways, resulting in limited cross-resistance with conventional cytotoxic therapy, exceptional tolerability and responses in patients refractory to numerous drug classes. Rare affinity to bone (osteotropism) results in highest drug concentrations in mineralized bone, with potential to treat cancers with bone involvement, e.g., metastases common in prostate, lung, and breast cancers, as well as blood cancers.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
President & CEO
Phosplatin Therapeutics